OPI, RVNC and AQST Are Among After Hour Movers
Seeking AlphaApr 22 16:53 ET
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session.The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with t
BenzingaApr 19 13:25 ET
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday.Shares of Fifth Third Bancorp (NASDAQ:FITB) rose during Friday's session after the company reported better-than-expe
BenzingaApr 19 10:40 ET
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Nasdaq Composite falling over 50 points on Thursday.Shares of Ally Financial Inc. (NYSE:ALLY) rose sharply during Thursday's session after the company reported better-
BenzingaApr 18 13:58 ET
Analysts' Top Healthcare Picks: Humacyte (HUMA), Janux Therapeutics Inc (JANX)
TipRanksApr 10 21:10 ET
Oppenheimer Keeps Their Buy Rating on Humacyte (HUMA)
TipRanksApr 8 08:25 ET
Humacyte Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Humacyte Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Dow JonesApr 1 08:39 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
Moomoo 24/7Apr 1 08:28 ET
Humacyte's HAV: A Game-Changer for Underserved Hemodialysis Patients
TipRanksMar 28 16:35 ET
Humacyte Price Target Maintained With a $4.00/Share by Piper Sandler
Humacyte Price Target Maintained With a $4.00/Share by Piper Sandler
Dow JonesMar 26 08:36 ET
Express News | Piper Sandler Maintains Neutral on Humacyte, Maintains $4 Price Target
Moomoo 24/7Mar 26 08:26 ET
Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)
TipRanksMar 26 07:06 ET
Humacyte to Host Virtual KOL Event "Hemodialysis Access: A Crossroads of Care," on March 28, 2024
PDF Version DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered hum
HumacyteMar 26 00:00 ET
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Benchmark analyst Bruce Jackson reiterates Humacyte with a Buy and maintains $15 price target.
Analyst UpgradesMar 25 10:46 ET
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/25/2024 362.96% Benchmark → $15 Reiterates Buy → Buy 03/08/2024 23.46% Piper Sandler $3 → $4 Maintains
BenzingaMar 25 10:45 ET
Humacyte's Strong Outlook: Buy Rating Affirmed Amid Advancements and Market Opportunity
TipRanksMar 23 10:35 ET
Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 23 10:16 ET
Buy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth Potential
TipRanksMar 22 13:35 ET
Earnings Call Summary | Humacyte(HUMA.US) Q4 2023 Earnings Conference
The following is a summary of the Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript:Financial Performance:Humacyte reported no revenue for both Q4 and the full year of 2023.Research and developme
moomoo AIMar 22 12:18 ET · Conference Call
Express News | Humacyte Q4 EPS $(0.24), Inline; Humacyte Says Its Cash And Cash Equivalents Of $80.4M, Net Proceeds Of $43.1M From The March Offering And Additional Draw Of $20M Under The Oberland Funding Arrangement, Will Provide Cash Runway For At Least 12 Months
Moomoo 24/7Mar 22 07:04 ET
No Data
No Data